University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, Alabama, USA.
Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Horm Res Paediatr. 2023;96(4):439-445. doi: 10.1159/000529126. Epub 2023 Jan 17.
There are two major categories of peroxisomal disorders (PDs): peroxisomal biogenesis disorders (PBDs) due to defects in peroxisomal (PEX) genes and deficiency of other peroxisomal enzymes (such as D-bifunctional enzyme deficiency due to HSD17B4). PDs are characterized by abnormal elevations of very-long-chain fatty acids (VLCFA). We aimed to evaluate the clinical phenotype of adrenal insufficiency in patients with PD and to assess any genotype-phenotype correlations with adrenal insufficiency.
We performed a retrospective electronic medical record review at a single university medical center, of data over 12 years and identified 7 patients with PD. Of the 7 patients identified, 6 patients had a diagnosis of PBD and one had a single peroxisomal enzyme deficiency, HSD17B4. The average age of the patients at diagnosis were 0.61 ± 0.66 years. Four patients (66.7%) had primary adrenal insufficiency: 3, out of the 4, patients had elevated baseline ACTH. Three patients failed to have increased response after the Cortrosyn™ stimulation test. Three patients were on daily hydrocortisone replacement, and 1 patient was on stress-dose hydrocortisone only as needed. Specific genetic variant analysis revealed that all the 3 patients with PBD and adrenal insufficiency who were on steroid supplementation had the compound heterozygous pathogenic variant in exon 13 of PEX1 c.2097dupT (p.Ile700Tyrfs*42) and c.2528G>A (p.Gly843Asp), while the 1 patient with peroxisomal enzyme deficiency and adrenal insufficiency had compound heterozygous pathogenic variants in HSD17B4 c.1369A>T (p.Asn457Tyr) and c.1210 - 1G>A (splice acceptor). Two of these patients with PEX1 variants also required mineralocorticoid supplementation. The 3 PBD patients without adrenal insufficiency did not have a PEX1 variant.
DISCUSSION/CONCLUSION: Primary adrenal insufficiency is common in patients with PD. Based on our data, patients with the compound heterozygous PEX1 pathogenic variants of exon 13 (c.2097dupT and c.2528G>A) tend to have adrenal insufficiency. Aldosterone deficiency, though rare, can occur in PD.
过氧化物酶体病(PDs)有两大主要类别:过氧化物酶体生物发生障碍(PBD),这是由于过氧化物酶体(PEX)基因缺陷所致;过氧化物酶体酶缺乏(例如由于 HSD17B4 缺乏导致的 D-双功能酶缺乏)。PD 的特征是异常升高的极长链脂肪酸(VLCFA)。我们旨在评估 PD 患者肾上腺功能不全的临床表型,并评估与肾上腺功能不全相关的任何基因型-表型相关性。
我们在一家大学医学中心进行了一项回顾性电子病历审查,研究了超过 12 年的数据,共确定了 7 名 PD 患者。在确定的 7 名患者中,有 6 名患有 PBD,1 名患有单一过氧化物酶体酶缺乏症,即 HSD17B4。患者的平均诊断年龄为 0.61±0.66 岁。4 名患者(66.7%)存在原发性肾上腺功能不全:其中 3 名患者基线 ACTH 升高。3 名患者在 Cortrosyn™ 刺激试验后反应无增加。3 名患者每天接受氢化可的松替代治疗,1 名患者仅在需要时接受应激剂量氢化可的松治疗。特定的基因变异分析显示,所有 3 名接受类固醇补充治疗的 PBD 合并肾上腺功能不全患者均携带 PEX1 外显子 13 的复合杂合致病性变异 c.2097dupT(p.Ile700Tyrfs*42)和 c.2528G>A(p.Gly843Asp),而患有过氧化物酶体酶缺乏症和肾上腺功能不全的 1 名患者则携带 HSD17B4 c.1369A>T(p.Asn457Tyr)和 c.1210-1G>A(剪接受体)的复合杂合致病性变异。这 2 名携带 PEX1 变异的患者还需要补充盐皮质激素。无肾上腺功能不全的 3 名 PBD 患者没有 PEX1 变异。
讨论/结论:原发性肾上腺功能不全在 PD 患者中很常见。根据我们的数据,携带外显子 13 的复合杂合 PEX1 致病性变异(c.2097dupT 和 c.2528G>A)的患者倾向于发生肾上腺功能不全。尽管醛固酮缺乏症很少见,但也可能发生在 PD 中。